Dr. Bernie on testosterone therapy for men on active surveillance
May 15th 2024“The 2018 AUA guidelines for testosterone therapy that were co-chaired by Dr. John P. Mulhall say that we have an absence or a paucity of data on using testosterone therapy on active surveillance,” says Helen L. Bernie, DO, MPH.
Dr. Soon-Shiong highlights data on N-803 in NMIBC
May 13th 2024"But more excitingly, as early as 9 months, even though they were small numbers, the comparison between BCG and Anktiva vs BCG alone showed a statistical significance in the duration of ongoing complete response," says Patrick Soon-Shiong, MD.
Blue light cystoscopy decreases risk of recurrence, progression in NMIBC
May 9th 2024“The results of the BRAVO study performed within the VA health care system showed significant decreases in the risk of recurrence and progression, as well as the potential for improved overall survival in patients who received a BLC compared to patients who received WLC only,” says Stephen B. Williams, MD, MBA, MS, FACS, FACHE.
Dr. Kutikov on retroperitoneoscopic partial nephrectomy for RCC
May 9th 2024“Also, the technique lends itself really nicely to these, what we call posterior ball-valve tumors, which are these tumors that sit behind the renal hilum, behind the blood vessels on the posterior side of the kidney,” says Alexander Kutikov, MD, FACS.
Dr. Psutka describes a study of at-home prehabilitation in MIBC
May 6th 2024"We've developed the Get Moving Trial, which is a randomized controlled phase 1/2 trial to demonstrate the safety, feasibility and efficacy of a home-based pre-op program that is personalized," says Sarah P. Psutka, MD, MSc.
Dr. Li on the design of the phase 3 MoonRISe-1 trial in NMIBC
May 6th 2024"So, in the MoonRISe-1 study, we're studying the efficacy of TAR-210 to prevent recurrence within the bladder by inserting the TAR-210 in the bladder every 3 months for up to 1 year, compared to intravesical chemotherapy," says Roger Li, MD.
UGN-102 treatment leads to meaningful DFS outcomes in NMIBC, regardless of prior TURBT
May 5th 2024A post hoc analysis of the phase 3 ATLAS trial showed that UGN-102 with or without TURBT induced meaningful disease-free survival and duration of response in patients with non–muscle-invasive bladder cancer.
Dr. Meeks highlights the recent innovation in bladder cancer
May 4th 2024"BCG worked well enough that we could give it to patients and it worked pretty well. But having the shortage, I think, has ultimately led to a bottleneck and then an explosion in the technology and the resources and the techniques to treat patients with non–muscle-invasive bladder cancer," says Joshua J. Meeks, MD, PhD.
Enzalutamide regimens increase undetectable PSA likelihood in nonmetastatic CSPC
May 4th 2024More patients with nonmetastatic castration-sensitive prostate cancer reached an undetectable PSA level if they received enzalutamide, as a single agent or combined with leuprolide, vs if they received leuprolide alone.